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Objectives: The aim of this study was to develop and validate a HPLC-MS/MS assay to determine total and
unbound concentrations of temocillin in serum samples.
Design and methods:Methanolic protein precipitation and ultrafiltration were used for total and unbound
concentration extraction, respectively. Extractwas injected into a LC-MS/MS system. Reversed phase chromatog-
raphywas performed on a phenyl grafted column in gradientmode. Temocillin and internal standard (ticarcillin)
were identified in positive electrospray ionization mode using ion transitions of m/z 415.34 N 339.1 and
385.31 N 160.3, respectively.
Results: Temocillin total and unbound concentration quantification assays were linear over concentrations
ranging from 1 to 500 mg/L and from 0.5 to 300 mg/L, respectively. Both assays presented acceptable intra and
inter-assay precision and accuracy b13.9%. Limits of quantification and detection were of 1 and 0.10 mg/L, and
0.5 and 0.05 mg/L for total and unbound concentration respectively. Total temocillin concentration recovery
ranged from 85.80 to 99.40%. Temocillin ion suppression effect was b36.2 % in both assays.
Conclusion: Themethod described is fast, sensitive and selective, with no interferences. Thismethodmay be
used for both pharmacokinetic studies and therapeutic drug monitoring purposes.© 2015 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.Introduction
Temocillin is a β-lactam antibiotic active against gram-negative
bacteria, including β-lactamase producers [1,2]. It is currently indicated
for the treatment of septicemia, urinary tract infections, and lower
respiratory tract infections [3]. In the recent years the interest on this
drug has been greatly enhanced, due to the increased incidence of infec-
tions caused by microorganisms producing extended-spectrum β-
lactamases. This makes temocillin a strategic and interesting alternative
to carbapenems, especially with the current driving force to spare the
use of these drugs [2].
Pharmacodynamic studies predict that therapeutic success
with β-lactams depends on the time during which their unbound5, 1200 Brussels, Belgium.
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ists. Published by Elsevier Inc. All rigconcentration in serum remains above the MIC of the offending organ-
ism [4]. Dosage should thus be adapted to take into account not only
the bacterial susceptibility, but also the rate of elimination of the drug.
There is evidence of a wide interindividual variability in the temocillin
serum levels so that standard dosing regimens may not be adequate in
special patient populations such as intensive-care and end-stage renal
disease patients [5,6]. These patients may benefit from individualized
dose regimens based on therapeutic drug monitoring.
Two validated assays (HPLC-UV) have been described in the lit-
erature to quantify temocillin. The first one was used for controlling
purity and detecting related substances in temocillin batches [7],
and the other one, for quantifying the drug in serum [8]. The later
method involves a laborious sample preparation with solid-phase
extraction to eliminate possibly interfering substances andwas validat-
ed for the total concentration only. The present work aims at validating a
new, rapid, sensitive and selective HPLC-MS/MS method for determi-
nation of both total and unbound concentrations of temocillin in
serum.hts reserved.
Fig. 2. Concentration–time profile for temocillin in the serum in a representative patient
(with end-stage renal disease) after administration of a 2 g dose IV. The graph shows
the total and unbound concentrations as determined by HPLC-MS/MS and the total con-
centration determined by HPLC-UV using a previously described method [8].
Fig. 1. Typical chromatograms. Ion chromatograms of serum extracts obtained either with a blank sample (A) or with a sample spiked simultaneously with temocillin at 1 mg/L (B) and
with ticarcillin as IS at 40 mg/L (C).
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Temocillin (∼68% R and ∼32% S isomers; NEGABAN®)was obtained
from Eumedica s.a. (Brussels, Belgium). Ticarcillin disodium (∼55% R
and ∼45% S isomers; internal standard, IS) was from Sigma-Aldrich
Inc. (St. Louis, MO, USA). Both molecules are chemically stable for at
least 24 h at 37 °C [9,10] and much longer at 4 °C [11,12]. HPLC/MS-
grade methanol and acetonitrile were purchased from J.T. Baker
(Deventer, Netherlands). Formic acid was obtained from Merck KGaA
(Darmstadt, Germany). Ultrapure water was obtained from MEDICA-R
7/15 water purification system (Veolia Water Systems, Bucks, UK) and
Milli-Q Academic apparatus (Millipore Corporation, Billerica, MA, USA).
Human drug-free serumwas obtained from healthy volunteers, in agree-
ment with local ethics guidelines.
The HPLC-MS/MS equipment consisted of a Quattro micro tandem
mass spectrometer (Micromass UK, Ltd., Manchester, UK) fitted with a
Z-spray ion source. The instrument was operated in electrospray
positive ionization (ESI) and coupled to a Waters 2795 HT, Alliance
HPLC system, with an integrated auto sampler (Waters, Mildford,
MA, USA). Data were recorded in the multiple reaction monitoring
(MRM) mode.
For determination of total temocillin concentrations, aliquots of
stock solutions prepared in water (10 mg/mL) were diluted with
drug-free serum to prepare 7 calibrators (CS) in the 1 to 500 mg/L
range. Quality control (QC) samples (5, 250, and 450 mg/L) were pre-
pared from an independent stock solution. Then, 200 μL of each CS or
QC were treated with 600 μL of methanol after addition of 32 μL of IS(1 mg/mL). After a 5 s vortex step, samples were centrifuged at
11,000 g. Ten microliters of the supernatant were injected into the
HPLC/MS-MS.
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serum was added to Amicon® Ultra-15 device, Centrifugal Filters
(NMWL 30 K; Merck Millipore Ltd.) and submitted to ultrafiltration
(2000 g, 25 °C, 20 min). The ultrafiltrate was used to dilute aliquots of
the temocillin stock solution in order to prepare 8 CS (0.5 to
300mg/L), andQC (0.75, 75, and 200mg/L). Twentymicroliters of IS so-
lution (0.2 mg/mL) were added to 100 μL of CS or QC. Ten microliters
were injected into the HPLC/MS-MS.
The analytical columnwas anXBridge® phenyl, 2.1 × 50mm, 3.5 μm
(Waters, Milford, MA, USA) maintained at 40 °C. The mobile phase
consisted of a mixture of solvents A (aqueous solution of 0.1% formic
acid) and B (0.1% formic acid in acetonitrile), under gradient conditions
and 0.3 mL/min flow rate. The auto sampler used a rinse solution of
0.1/50/50 formic acid/water/acetonitrile (v/v/v). The total run time was
6 min. The transitionsm/z 415.34 N 339.1 andm/z 385.31 N 160.3 were
used for temocillin and IS quantification, respectively. The cone voltages
(CoV) and collision energies (CE) optimized for the method were 20 V
and 25 V, and 12 and 14 eV, respectively for temocillin and IS.
Ion transitions m/z 415.34 N 172.2 (CoV = 20 V, CE = 35 eV) and
m/z 385.31 N 243.3 (CoV = 20 V CE = 23 eV) were used for
temocillin and IS qualification, respectively.
The assay was fully validated according to the U.S. Food and
Drug Administration (FDA) guidelines [13]. Statistics were performed
using JMP software (SAS Institute, Cary, NC, USA). The linearity has been
assessed over the 7 and 8 calibrators (total and unbound concentration,
respectively), in 5 replicates over 3 days. The limit of quantification
(LOQ) was calculated as the minimum concentration at which temocillin
can be reliably quantified with a precision ≤20% and accuracy within
−20–20%. The limit of detection (LOD) was calculated as the smallest
detectable peak above baseline noise (signal-to-noise ratio N3:1). Inter-
assay precision and accuracy were assessed on QC samples and the LOQ,
in replicates of 5 for 3 days. To determine intra-assay accuracy and
precision, the same samples were analyzed 5 times. Extraction effi-
ciency of temocillin from serum was performed by comparing con-
centrations recovered from samples treated as described above for
the determination of total concentration with unextracted calibra-
tors (6 replicates for the 3 QC concentrations). Matrix effect was
assessed against the QC samples using the post-extraction addition
technique using 6 different drug-free serum samples for each aliquot
[14]. The suitability of IS to minor matrix effect was assessed by compar-
ing calibration curves made in HPLC solvent A and in 6 different serum
samples with and without IS.
Results
The correlation coefficient (R2) for each calibration curve was N0.99,
with a mean value of 0.993 and 0.995 for the total (n = 15) and
unbound (n= 15) temocillin concentration, respectively. LOQ and LOD
were found to be 1 and 0.10 mg/L (total concentration) and 0.50 and
0.05 mg/L (unbound concentration). As shown in Fig. 1, the retention
times (RT) were 3.14 and 3.18 min for temocillin and IS, respectively.
For the total concentrations, inter-assay (3 days; n = 15) precision
and accuracy ranged from6.48 to 8.88% and from 2.26 to 11.64% respec-
tively, while the intra-assay (3 days; n = 5) precision and accuracy
ranged from 7.14 to 9.18% and from 6.86 to 13.91% respectively. For
the unbound concentrations, inter-assay (3 days; n = 15) precision
and accuracy ranged from 3.4 to 4.8% and from 3.3 to 7.6%, with an
intra-assay (3 days; n= 5) precision and accuracy ranging from 1.1 to
6.7% and from 8.4 to 12.5%, respectively.
Temocillin extraction recovery ranged from 85.8 to 99.4% with
a precision ranging from 7.5 to 11.9%, and appeared concentration inde-
pendent. No interfering peak greater than 20% of the response at the
LOQ was detected at them/z transitions and RT of temocillin and IS. Typ-
ical ion chromatograms of extracts from blank serum sample, serum
spiked with temocillin (1 mg/L) and ticarcillin (40 mg/L) are shown in
Fig. 1.At the three QC levels, matrix effect was acceptable, ranging from
−36.2 to−17.3% ion suppression for both temocillin and IS. This effect
was significantly corrected using ticarcillin as IS. Indeed, the function
slope between calibration curves made in HPLC solvent A and different
serum samples was comparable (mean = 0.571; CV = 4.8%; n = 7).
The results of these experiments suggested that matrix effects have min-
imal influence on the results.
This method was then applied to determine the concentration–time
profile of total and unbound temocillin for temocillin in the serum of an
end-stage renal disease patient, having received 2 g of temocillin by IV
route. As shown in Fig. 2, total concentration matched those determined
by a previously validated HPLC-UV method [6]. Unbound concentrations
oscillated between 24% at 0.5 h and 13% at 44 h. Unbound AUC represent-
ed 14%of the total value. These observations are in linewithwhat is stated
in the summary of product characteristics, namely that the unbound frac-
tion depends on the total concentration due to saturation of binding sites
on serum proteins and that the protein binding is about 85% for total
concentrations around 16 mg/L [3].Conclusion
The HPLC-MS/MS method described in this work for the quantifica-
tion of total and unbound temocillin in human serumproved rapid, sen-
sitive, and selective, with a LOQ of 1mg/L. As MS/MS detection is highly
specific, this method has probably a wider applicability to different clin-
ical situations than the previously developed HPLC-UV assay [8], like in
patients receiving other medications or in hemodialysis patients who
accumulate acidic metabolites [15].Acknowledgments
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